author-photo

Jeffrey A. Stafford

Takeda Pharmaceutical Company

43

Papers

1498

Citations

Citation Trend

Filter By

Papers (42) Sort By

Journal Conference Others

Abstract 2128: TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
210P TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (14)
Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors

2019 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (3)
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.

2018 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (4)
POLYTHÉRAPIE PAR INHIBITEUR DE PROTÉINE À BROMODOMAINE ET DOMAINE EXTRA-TERMINAL

2018
- Robert Cho
- Jeffrey A. Stafford
Show All
- Source
- Cite
- Save
Citations (0)
Discovery of Inhibitors of NLRP3 inflammasome assembly for the treatment of NASH and liver fibrosis

2018 Journal of Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
Structure-based design and discovery of potent and selective KDM5 inhibitors.

2018 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (20)